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The objective of this study was to evaluate the impact of whole- and sub-population-related variabilities on the determination of
the human kinetic adjustment factor (HKAF) used in risk assessment of inhaled volatile organic chemicals (VOCs). Monte Carlo
simulationswereappliedtoasteady-statealgorithmtogeneratepopulationdistributionsforbloodconcentrations(CAss)andrates
of metabolism (RAMs) for inhalation exposures to benzene (BZ) and 1,4-dioxane (1,4-D). The simulated population consisted
of various proportions of adults, elderly, children, neonates and pregnant women as per the Canadian demography. Subgroup-
speciﬁcinputparameterswereobtainedfromtheliteratureandP3Msoftware.Underthe“wholepopulation”approach,theHKAF
was computed as the ratio of the entire population’s upper percentile value (99th, 95th) of dose metrics to the median value in
either the entire population or the adult population. Under the “distinct subpopulation” approach, the upper percentile values
in each subpopulation were considered, and the greatest resulting HKAF was retained. CAss-based HKAFs that considered the
Canadian demography varied between 1.2 (BZ) and 2.8 (1,4-D). The “distinct subpopulation” CAss-based HKAF varied between
1.6 (BZ) and 8.5 (1,4-D). RAM-based HKAFs always remained below 1.6. Overall, this study evaluated for the ﬁrst time the impact
of underlying assumptions with respect to the interindividual variability considered (whole population or each subpopulation
taken separately) when determining the HKAF.
1.Introduction
An interindividual variability (or uncertainty) factor (IVF)
of a default value of 10 is usually applied to the point
of departure (POD) for deriving reference doses (RfDs)
or reference concentrations (RfCs) for use in noncancer
risk assessment [1–3]. As reviewed by Price et al. [4], the
IVF has historically been deﬁned as a factor required to
protect the sensitive members of the population since the
POD is generally determined for average healthy individuals.
Actually,twomodelshavebeenproposedtodescribetheIVF.
Under the “sensitive population” model, the IVF is applied
to correct for the possible failure of a critical study to include
as u ﬃcient number of members pertaining to distinct sub-
population exhibiting an increased sensitivity. Conversely,
under the “ﬁnite sample size” model, the application of the
IVF relates to the possibility that the retained POD may fail
to identify the toxicity threshold in the overall population
simply because of the ﬁnite size of the sample in which it
was determined [4]. Thus, the IVF accounts for the overall
biological variability in the human population.
In the last 20 years, the IVF has been divided into two
constitutive components (toxicokinetic and toxicodynamic
factors), equal to 3.16 each based on pharmaceutical data
[5–7]. This subdivision can be used in the evaluation of the
magnitude and adequacy of the IVF for speciﬁc chemicals,
and its replacement when appropriate data are available,
by quantifying chemical-speciﬁc adjustment factors (CSAFs)
[8, 9]. Under this method, the CSAF for interindividual
variability in toxicokinetics, also referred to as the human
kinetic adjustment factor (HKAF), can be determined based
on the population distributions of relevant pharmacokinetic
parameters (e.g., half-life, maximal concentration). The
HKAF is calculated as the ratio between the upper percentile2 Journal of Toxicology
Table 1: Chemical-speciﬁc parameters used in the steady-state
algorithm.
Parameter
Chemical
Benzene(a) 1,4-Dioxane(b)
Vmaxc (mg/h-kg0.75) 2.11 0.27
Km (mg/L) 0.1 3.0
Blood:air partition
coeﬃcient (Pb) 7.4 3650
Exposure concentration
(mg/m3,U F× RfC)(c) 0.3 3
(a)[22]. (b)[23]. (c)[10].
BW: body weight; Km: Micha¨ elis-Menten constant, Pb: blood:air partition
coeﬃcient, RfC: reference concentration; UF: interindividual uncertainty
factor; Vmaxc: constant maximum rate of metabolism.
valueofaparameter(i.e.,95th)anditscentraltendencyvalue
(i.e., median) in the whole population or between an upper
percentile value in a presumed susceptible subpopulation
and the central tendency value in the general healthy
population [8, 9].
Neither the historical deﬁnitions of IVF [4] nor the IPCS
guidancedocumentonCSAFs[8]clearlydeﬁnesthe“average
healthy individual,” forming the point of comparison for
the presumed sensitive subpopulations. Particularly, it is
unclear as to whether this individual is the average healthy
adult or the average healthy individual from the whole
population (which includes both healthy adults and sensitive
subpopulations). But presumably because the POD used to
derive the RfD or RfC is generally determined in healthy
adults (animal or human) [10], HKAF evaluations con-
ducted using experimental data for drugs [11–13] or PBPK
model simulation data for environmental toxicants [14–16]
have relied on what can be called a “distinct subpopulation”
approach. Thus, the experimental or simulated data in the
presumed susceptible individuals (e.g., neonates, pregnant
women, elderly, polymorphic individuals) have often been
compared with the corresponding data in healthy adults.
Alternatively, HKAF can be quantiﬁed using a “whole
population” approach as done recently by M¨ ork and Johan-
son [17]. In this study, HKAFs were calculated for inhaled
acetone based on a simulated distribution of steady-state
blood concentration in an entire population, including
adultsandvariousage-deﬁnedgroupsofchildren.ThePBPK
modeling results in the diﬀerent subgroups were weighted
accordingtodemographicrepresentationinSweden.Exclud-
ing the endogenous production of acetone, an HKAF of 1.9
was obtained by dividing the 95th percentile value of the
entire population by the median. In comparison, using the
95th percentile value of that same dose metric in 3-month-
o l db a b i e sa sw e l la s1 0a n d1 5 y ro l dc h i l d r e nr e s u l t e di n
HKAFs of 2, 2.4, and 1.7, respectively.
The hypothesis that the HKAF determined upon the
“whole population” approach is quite diﬀerent from the one
determined based on the “distinct subpopulation” approach
stems from the results of M¨ ork and Johanson [17]. This
potential diﬀerence could be signiﬁcant from a regulatory
standpoint because it may not lead to comparable levels
of protection for the diﬀerent subgroups that compose
the whole population. It is also not known whether the
population composition and the chemical considered may
impact this potential diﬀerence. Thus, the objective of the
currentstudywastoevaluatethemagnitudeandadequacyof
the HKAFs determined by the “whole population” approach
as compared to the “distinct subpopulation” approach. In
eﬀect, population distributions of internal dose metrics
following chronic exposure to two chemicals exhibiting
diﬀerent clearance characteristics were used to compute the
HKAF as
(i) the ratio of the upper percentile value in the entire
population including adults and nonadults over the
median in adults and in this entire population;
(ii) the ratio of the upper percentile value in presumed
susceptible subpopulation over the median in adults
and in the entire population including adults and
non-adults.
2. Methods
A physiologically based steady-state algorithm combined
with Monte Carlo simulation software was used to generate
population distributions of blood concentration (CAss) and
rate of metabolism (RAM) for chronic inhalation exposure
to two chemicals with contrasting systemic clearance char-
acteristics. The population distributions were reconstructed
b a s e do nd i ﬀerent proportions of randomly selected adults,
elderly, children, neonates, and PW, and they were used to
compute HKAFs based on “whole population” and “distinct
subpopulation” approaches.
2.1. Selection of Surrogate Chemicals and Their Speciﬁc
Parameters. Two VOCs were chosen as surrogate chemicals
because they exhibit contrasting systemic clearances based
on their pulmonary clearance potential (diﬀerent blood:air
partition coeﬃcient (Pb)) and their hepatic clearance (dif-
ferent hepatic extraction ratios). Benzene was chosen as an
extensively cleared chemical because of its high pulmonary
clearance (low Pb, 7.4) and high hepatic extraction ratio.
Conversely, 1,4-dioxane was chosen as a poorly cleared
chemical due to its low pulmonary clearance (Pb = 3650)
and low hepatic extraction ratio. While benzene is a known
substrate of CYP2E1 [18], for which extensive data on
interindividual variability are available [19, 20], 1,4-dioxane
was included in this study to facilitate the coverage of a range
of physico/biochemical properties of potential substrates of
CYP2E1 [21]. Chemical-speciﬁc parameters are indicated in
Table 1 and were taken from the literature [10, 22, 23]. The
choice of these two surrogate VOCs and associated kinetic
parameters was undertaken to reﬂect the range of kinetic
characteristics of hypothetical substances for evaluating the
HKAF. As such, the present modeling study did not focus
on any aspect of the risk assessment relating to these speciﬁc
chemicals.
2.2. Use of a Biologically Based Steady-State Model for the
Simulation of Continuous Inhalation Exposure in Diﬀerent
Subpopulations. The current study relies on the use ofJournal of Toxicology 3
a steady-state model for inhalation exposures (e.g., [24–
27]), because the current study aimed at reconstructing
population distributions of internal dose metrics for con-
tinuous lifetime exposures. Brieﬂy, the algorithm computes
the arterial blood concentration at steady-state (CAss) from
the alveolar ventilation rate (Qp), the concentration in air
(Ci), and the hepatic (Ql × Ehep) and pulmonary (Qp/Pb)
clearances [27]:
CAss =
Qp ×Ci
Ql ×Ehep +Qp /Pb
,( 1 )
where Ql is the liver blood ﬂow, Pb is the blood:air partition
coeﬃcient, and Ehep is the hepatic extraction ratio of the
chemical and is calculated from its intrinsic clearance (Clint)
as follows:
Ehep =
Clint
Clint + Ql
. (2)
Also, the rate of metabolised parent compound per unit
volume of liver (RAM) is calculated as
RAM =
CAss ×Ql ×Ehep
Vl
. (3)
As indicated in Table 2,Q p ,Q l ,a n dV lw e r ec a l c u l a t e df o r
a given individual by applying equations derived from Price
etal.[28]totheindividual’sbodyweight[16].Theinputdata
are listed in Table 2 for each subpopulation considered [15,
16, 19, 20, 28, 29]. These include six age groups covering the
lifespan (neonates (0–30d), infants (1–12mo), toddlers (1–
3yr), children/adolescents (4–17yr), adults (18–64yr), and
elderly(65–90yr)),aswellaspregnantwomen(15–44yr).Ql
and Vl for pregnant women were actually calculated on the
basis of the body weight for nonpregnant women, whereas
the appropriate increase in alveolar ventilation rate at any
time during pregnancy was accounted for when computing
Qp [16].
2.3. Generation of Distributions of Internal Dose Metrics
by Means of Monte Carlo Simulations. Constant inhalation
exposure to a benzene concentration corresponding to 10×
the RfC (Table 1) was simulated in each subpopulation.
Given the lack of an RfC for 1,4-dioxane, and its approx-
imately tenfold greater RfD compared to benzene [10], a
concentration that was ten times greater than the benzene
concentration was speciﬁed. Monte Carlo simulations were
performed using the Crystal Ball software (Oracle, Redwood
Shores, CA) to generate distributions of the various internal
dose metrics (see below). The intrinsic clearance in (2)
was corrected for a given individual in any subpopulation
by adjusting the maximum rate of metabolism (Vmaxind)
using enzyme-speciﬁc catalytic turnover [14–16]. This was
determined based on the Vmax in an adult of average body
weight (BWavg ad), as well as the (individual (ind)/average
adult (avg ad)) ratios of the liver volumes and CYP2E1
hepatic content (in pmol/mg of microsomal protein):
V maxind
=
Vmaxc ×BWavg ad
0.75
[CYP2E1]avg ad ×Vlavg ad
× [CYP2E1]ind ×Vlind.
(4)
A constant hepatic microsomal protein concentration was
assumed across the subpopulations as discussed in Valcke
and Krishnan [16].
2.3.1. Distributions in the “Whole Population” and Corre-
sponding HKAFs. Distributions of the internal dose metrics
were generated for a theoretical population of 100,000
people with the demographic characteristics of Canada [30].
Therefore, the number of iterations used in the Monte Carlo
simulations for each subpopulation corresponded to the
targeted number of individuals. This number was based
on the demographic proportions of each subpopulation
(Table 3). Because the number of individuals appeared rel-
atively constant across census’ age ranges of same duration,
the number of individuals pertaining to an age range
diﬀerent than those deﬁned in the census could easily be
estimated. For example, the number of toddlers aged 1–3
was considered as 60% of the total individuals 0–4yr old.
Finally, the number of pregnant women was calculated based
on the pregnancy rate of 104/1,000 from Ventura et al. [31]
and on the number of women aged 15–44yr from the census
data. The dose metric values “generated” by the Monte Carlo
simulations for each subpopulation were then merged into
a single “Canadian population dataset” of 100,000 values.
To calculate the HKAFs based on the “whole population”
approach, the ratio of the upper percentile value of the
dose metric in the entire Canadian population to its median
value was computed. The percentage of each subpopulation
that was protected by a “whole population” HKAF was
determined by identifying the number of individuals in each
subpopulation exhibiting an internal dose metric that was
lower than the entire population’s upper percentile value
underlying the HKAF, that is, 95th or 99th.
2.3.2. Distributions in Each “Distinct Subpopulation” and
Corresponding HKAFs. Distributions of the internal dose
metrics for 100,000 individuals of each subpopulation
were generated and the chemical- and dose-metric-speciﬁc
HKAFs were calculated based on the “distinct subpopula-
tion” approach, that is, as the ratio of the upper percentile
value(i.e.,95thor99th)ineachsubpopulationtothemedian
value in adults or the whole Canadian population (see
above). Also, for a given dose metric, the greatest “distinct
subpopulation-” based HKAF was multiplied by the median
in the whole Canadian population (see above) to obtain a
threshold dose metric value. This threshold corresponded
to the percentile that was referred to for determining the
proportion of individuals from the entire population that
was covered by the greatest “distinct subpopulation” HKAF.4 Journal of Toxicology
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Table 3: Reconstruction of the hypothetical populations of 100,000 people with the Canadian demographic proﬁle.
Canadian population in 2009(a)
Subpopulation (age range) Median age = 39.7yr
Population size (%) Corresponding reconstructed population size and
number (n) of Monte Carlo iterations
Adults (18–64) 21,685,253 (63.92) 63,923
Neonates (0–30d) 31,303 (0.09) 93
Infants (1–12mo) 344,329 (1.02) 1,015
Toddlers (1–3) 1,126,896 (3.32) 3,322
Children and adolescents
(4–17) 5,382,420 (15.87) 15,866
Elderly (65–90) 4,634,673 (13.66) 13,662
Pregnant women(b) (15–44) 718,950 (2.12) 2,119
TOTAL 33,923,824 (100) 100,000
(a)[30]. (b)Based on a pregnancy rate of 104/1,000 in U.S. women aged 15–44 yr [31].
2.4. Evaluation of the Impact of Demography on the Computed
HKAFs. Given that the HKAF values as computed herein
rely on the distribution of internal dose metrics in a
general population composed of various proportions of each
subpopulation, it was hypothesized that the demographic
characteristics of a given general population may impact this
calculation. To test this hypothesis, HKAFs were evaluated
on the basis of dose metric distributions generated for a
theoretical “younger population.” These distributions were
reconstructed by multiplying by 3 the number of individuals
of each subpopulation <1 8y r ,a sw e l la sp r e g n a n tw o m e n ,
as compared to the numbers that were previously used to
reconstruct the Canadian population distributions (Table 3).
The number of adults was also adjusted to maintain a total
of 100,000 dose metric values. Thus, more than 60% of the
resulting “younger population” was aged <18y, as compared
to approximately 20% for the Canadian population.
3. Results
3.1. Distributions of Internal Dose Metrics in Each Subpopu-
lation and the Entire Canadian Population. Figures 1 and 2
show the simulation of internal dose metric distributions in
each subpopulation (making up the entire Canadian popula-
tion) exposed to benzene and 1,4-dioxane, respectively. The
shapes of the Canadian population distributions appeared
normalforCAssofbenzeneandlognormalintheothercases.
The ranges (1st–99th percentile) and median dose metrics
that were obtained when simulating 100,000 individuals
in each subpopulation are indicated in Table 4.B a s e do n
the median and 99th percentile dose metrics, neonates and
pregnant women were the most susceptible subpopulations
(i.e., they exhibited the highest dose metric) based on CAss
and RAM, respectively. The median dose metric in the
most susceptible subpopulation was always greater than
the median dose metric in the Canadian population, but
it was lower than the 99th percentile value, except for
the CAss value for 1,4-dioxane. In this case, the median
value in neonates (2.3mg/L) was greater than the 99th
percentile value in the whole population (2.14mg/L). The
internal variability of internal dose metrics in the Canadian
population can be appraised by the ratio of the 99th to the
1st percentile values. The greatest variability was obtained
for 1,4-dioxane based on simulations of CAss exhibiting an
approximately sevenfold diﬀerence. The population variabil-
ity was lower in every other case ((99th/1st percentile) ratios
lower than 3). Similar trends were obtained for each speciﬁc
subpopulation, although the magnitude of the diﬀerences
varied. In particular, neonates exhibited a tenfold (99th/1st
percentile) ratio of CAss for 1,4-dioxane. This dose metric
exhibits a variability leading to such ratio that is always
greaterthan5 regardlessof the subpopulation. In everyother
subpopulation and dose metric, the ratio was at most equal
to 3 (neonates’ RAM for 1,4-dioxane).
3.2. HKAF Values
3.2.1. “Whole Population” Approach. HKAFs determined
based on the “whole population” approach, which used
both the median adult (HKAFad) and the median individual
in the entire Canadian population (HKAFpop) as referents,
are indicated in Table 5. CAss-based HKAFs varied between
1.2 and 1.3 for benzene and between 2.1 and 2.8 for 1,4-
dioxane. These values were slightly lower than the highest
“distinctsubpopulation-”basedHKAFsforbenzenebutwere
signiﬁcantly lower than the 1,4-dioxane values (see below).
Considering the RAM, all the HKAF values were between 1.2
and 1.6 regardless of the chemical. These values were slightly
lower than the highest RAM-based HKAFs obtained with the
“distinct subpopulation” approach in pregnant women (1.5–
2.1, see below).
3.2.2. “Distinct Subpopulation” Approach. Table 5 shows that
the 95th and the 99th percentile-based HKAFs that were
computed using the “distinct subpopulation” approach were
comparable whether the median adult (HKAFad) or the
median individual in the whole population (HKAFpop)w a s
used as a referent. In addition to the referent adults, results
for neonates and pregnant women are presented because6 Journal of Toxicology
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Figure 2: Distributions of individual values obtained for CAss (a) and RAM (b) in each subpopulation within the whole Canadian
population for constant inhalation exposure to 1,4-dioxane. From top to bottom, the distributions are shown for the entire Canadian
population (thick —), adults (—), children and adolescents (—–), elderly (–·–·–), toddlers (––-), pregnant women (-------), infants (-·-·-
·-), and neonates (indistinguishable).
they were, toxicokinetically, the most susceptible based on
their respective CAss and RAM (Table 4). HKAFs for infants
were also shown because they exceeded the default 3.16
value when CAss of 1,4-dioxane was considered, on the
basis of the 99th percentile value (3.8). The default value
was also exceeded based only on CAss of 1,4-dioxane in
neonates (range: 6.5–8.5) and the 99th percentile value in
pregnantwomen(3.5).NeonatesexhibitedthegreatestCAss-
based HKAFs for inhaled benzene (1.6–1.7). Otherwise,
pregnant women showed the greatest RAM-based HKAFs
for benzene (1.5–1.6) and 1,4-dioxane (1.8–2.1). HKAFs in
other subpopulations remained in the range of the HKAFs
presented in Table 5 for any given dose metric (data not
shown).
3.3. Proportions of the Whole Population or the Distinct
Subpopulations Covered by the Diﬀerent HKAFs. Table 6
shows the proportion of each subpopulation that was
covered by the various HKAFs deﬁned using the “whole
population” approach. The 95th or 99th percentile-based
“whole population” HKAFs generally protect at least, or very
close to, 95% and 99%, respectively, of the individuals of
each subpopulation. However, only 57% of the neonates,
78% of the pregnant women, and 89% of the infants were
covered by the 95th percentile-based “whole population,”
CAss-based HKAF for benzene. Corresponding values for
the 99th percentile-based HKAF values were 73%, 92%, and
97%, respectively. In the case of 1,4-dioxane, 27%, 76%, and
86% of the neonates, infants, and pregnant women wereJournal of Toxicology 7
Table 4: Distribution statistics of various dose metrics in each subpopulation based on 100,000 Monte Carlo iterations and the entire
Canadian populations for constant inhalation exposure.
Subpopulation
Statistics
Dose metrics
Benzene 1,4-Dioxane
CAss RAM CAss RAM
Adults
1st percentile 0.76 35 285 531
Median 1.04 46 763 806
99th percentile 1.36 62 2119 1291
Neonates
1st percentile 0.88 20 682 371
Median 1.26 39 2299 686
99th percentile 1.76 55 6486 1149
Infants
1st percentile 0.8 33 420 526
Median 1.11 45 1150 787
99th percentile 1.44 60 2928 1246
Toddlers
1st percentile 0.79 35 382 534
Median 1.08 47 968 804
99th percentile 1.38 60 2099 1271
Children and adolescents
1st percentile 0.77 35 352 538
Median 1.04 47 774 814
99th percentile 1.35 61 1744 1293
Elderly
1st percentile 0.76 35 286 530
Median 1.04 46 766 807
99th percentile 1.37 62 2144 1291
Pregnant Women
1st percentile 0.85 41 372 673
Median 1.16 55 995 1050
99th percentile 1.49 73 2698 1686
Canadian population
1st percentile 0.76 35 299 533
Median 1.04 47 779 808
99th percentile 1.36 63 2139 1306
CAss: blood concentration of parent compound (µg / L ) ;R A M :r a t eo fm e t a b o l i s m( µg / h - Lo fl i v e r ) .
covered by the 95th percentile-based HKAF, respectively.
Corresponding values for the 99th percentile HKAFs were
48%, 92%, and 96%, respectively, and the default 3.16 factor
appears to cover only 60% of the neonates. Considering
the RAM, the lack of coverage by the “whole population-”
based HKAF concerns pregnant women, as only 63% and
85% of them are covered by, respectively, the 95th and 99th
percentile-based HKAF for benzene. These numbers are 66%
and 86% in the case of 1,4-dioxane. Finally, when the HKAF
was computed with the “distinct subpopulation” approach
and the greatest value was retained, more than 99% of
the entire Canadian population was covered for every dose
metric considered (Table 6).
3.4. Impact of the Demography on the Computed HKAFs.
The impact of the demographic characteristics on the HKAF
values as computed herein can be appreciated from the
results shown in Figure 3 for CAss and Figure 4 for RAM.
The distributions for 100,000 referents (adult) and the
most susceptible individuals (neonates for CAss, pregnant
women for RAM) are also shown in these ﬁgures for
comparison purposes. For benzene (Figure 3(a)), the change
in demographics did not impact the overall population
distribution of CAss (indistinguishable from adults) and
thus, not the HKAF. The change of demographics shifts
minimally to the right the population distribution of CAss
for 1,4-dioxane (Figure 3(b)). The impact on the various8 Journal of Toxicology
Table 5: HKAFs obtained by the “distinct subpopulation” approach on the basis of 100,000 Monte Carlo iterations in adults, neonates,
infants, and pregnant women and by the “whole population” approach for the Canadian population.
HKAF assumption
Dose metrics
Benzene 1,4-Dioxane
CAss RAM CAss RAM
“Whole population” approach
HKAFad
(a)
Based on 95th percentile 1.2 1.3 2.1 1.4
Based on 99th percentile 1.3 1.4 2.8 1.6
HKAFpop
(b)
Based on 95th percentile 1.2 1.2 2.1 1.4
Based on 99th percentile 1.3 1.4 2.8 1.6
“Distinct subpopulation” approach
In adults
HKAFad
(c)
Based on 95th percentile 1.2 1.2 2.1 1.4
Based on 99th percentile 1.3 1.3 2.8 1.6
HKAFpop
(d)
Based on 95th percentile 1.2 1.2 2.0 1.4
Based on 99th percentile 1.3 1.3 2.7 1.6
In neonates
HKAFad
(c)
Based on 95th percentile 1.6 1.1 6.6 1.2
Based on 99th percentile 1.7 1.2 8.5 1.4
HKAFpop
(d)
Based on 95th percentile 1.6 1.1 6.5 1.2
Based on 99th percentile 1.7 1.2 8.3 1.4
In infants
HKAFad
(c)
Based on 95th percentile 1.3 1.2 3.1 1.4
Based on 99th percentile 1.4 1.3 3.8 1.6
HKAFpop
(d)
Based on 95th percentile 1.3 1.2 3.0 1.4
Based on 99th percentile 1.4 1.3 3.8 1.5
In pregnant women
HKAFad
(c)
B a s e do n9 5 t hp e r c e n t i l e 1 . 4 1.5 2.7 1.8
B a s e do n9 9 t hp e r c e n t i l e 1 . 5 1.6 3.5 2.1
HKAFpop
(d)
B a s e do n9 5 t hp e r c e n t i l e 1 . 4 1.5 2.6 1.8
B a s e do n9 9 t hp e r c e n t i l e 1 . 5 1.6 3.5 2.1
Italicized values indicate the highest HKAF among each subpopulation for a given dose metric.
(a)Computed as the ratio of the upper percentile value in the Canadian population (95th or 99th) to the median in 100,000 adults. (b)Computed as the
ratio of the upper percentile value in the Canadian population (95th or 99th) to its median. (c)Computed as the ratio of the upper percentile value in the
subpopulation (95th or 99th) to the median in adults. (d)Computed as the ratio of the upper percentile value in the subpopulation (95th or 99th) to the
median in the Canadian population.
CAss: blood concentration of parent compound; HKAF(ad/pop): human kinetic adjustment factor using either the median in adult (“ad”) or whole population
(“pop”) as referent; RAM: rate of metabolism.Journal of Toxicology 9
Table 6: Percentage of individuals in the diverse Canadian subpopulations that are covered by the HKAF and the default factor for various
dose metrics and chemicals.
Subpopulation Variability descriptor Dose metrics
Benzene 1,4-Dioxane
CAss (%) RAM (%) CAss (%) RAM (%)
Adults
“whole population”(a) HKAF95th 96 96 95 97
“whole population”(a) HKAF99th 99 >99 >99 >99
Default 3.16 factor 100 100 >99 100
Neonates
“whole population”(a) HKAF95th 57 100 27 100
“whole population”(a) HKAF99th 73 100 48 100
Default 3.16 factor 100 100 60 100
Infants
“whole population”(a) HKAF95th 89 97 76 97
“whole population”(a) HKAF99th 97 >99 92 >99
Default 3.16 factor 100 100 97 100
Toddlers
“whole population”(a) HKAF95th 93 97 92 96
“whole population”(a) HKAF99th 99 >99 99 99
Default 3.16 factor 100 100 >99 100
Children and adolescents
“whole population”(a) HKAF95th 96 96 98 95
“whole population”(a) HKAF99th >99 >99 >99 >99
Default 3.16 factor 100 100 100 100
Elderly
“whole population”(a) HKAF95th 95 96 95 96
“whole population”(a) HKAF99th >99 99 99 >99
Default 3.16 factor 100 100 >99 100
Pregnant Women
“whole population”(a) HKAF95th 78 63 86 66
“whole population”(a) HKAF99th 92 85 96 86
Default 3.16 factor 100 100 98 100
Canadian population
Greatest(b) “distinct subpopulation” HKAF95th >99 >99 >99 >99
Greatest(b) “distinct subpopulation” HKAF99th >99 >99 >99 >99
Default 3.16 factor 100 100 >99 100
(a)Based on the median value in the whole Canadian population. (b)Based on the median value in adults in Table 5.
CAss: blood concentration of parent compound (µg / L ) ;R A M :r a t eo fm e t a b o l i s m( µg / h - Lo fl i v e r ) .
HKAFs was low (“whole population” HKAF = 2.69 versus
2.75) with diﬀerences of 3% or less for the relevant
statistical descriptors. Considering RAM, when the number
of signiﬁcantly less susceptible neonates, and infants, and
more susceptible pregnant women, was increased at the
expense of adults, the entire population distribution of
the dose metric for both chemicals was widened slightly
and particularly for 1,4-dioxane (Figure 4). The impact of
pregnant women was apparent with a slight burst in the
“younger” population distribution, which was observed near
the pregnant women’s approximate median value. On the
basis of the 99th percentile values, this resulted in virtually
unchanged HKAFs for benzene (Figure 4(a)), but marginal
changes were observed for 1,4-dioxane (Figure 4(b)). The
“whole population” HKAFs that were calculated from the
indicated statistical descriptors are 1.67 (1342/806) and 1.75
(1342/765), which were based on median values in adults
or population distributions, respectively, for the “younger”
population. In comparison, the “whole population” HKAF
for the Canadian population was 1.62. The “distinct sub-
population” HKAF for pregnant women was also slightly
increased, from 2.09 for the Canadian and adult populations
to 2.2 for the “younger” population due to lower median
values (765µg/h-L of liver versus 808 or 806µg/h-L of liver).10 Journal of Toxicology
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4. Discussion
This study performed Monte Carlo simulations on a steady-
state algorithm to reconstruct representative subpopulation
and whole population distributions of internal dose metrics
forcontinuousinhalationexposuretoahighly(benzene)and
poorly (1,4-dioxane) cleared chemical. This allowed evalu-
ating the impact of various assumptions on the resulting
HKAF.
Virtual populations have been reconstructed to evaluate
the population variability of the pharmacokinetic of drugs
(e.g., [32, 33]), but to date, the same approach had not been
realized for environmental contaminants. This procedure
realized in the context of the present study allowed obtaining
results showing that the impact of the approach chosen
to compute the HKAF depends on the chemical and dose
metric considered. The “whole population” approach used
here can be related to the “Finite Sample Size” model of IVF
from Price et al. [4], whereas the “distinct subpopulation-”
based HKAF can be associated to these authors’ “sensitive
population” model. When the most sensitive individuals,
based on dosimetric considerations, constitute a very small
fraction of the entire population, a “whole population-”
based HKAF might not be suﬃcient to cover them ade-
quately. For instance, less than 60% of the neonates, consti-
tuting less than 0.1% of the whole Canadian population in
this study, were covered by the “whole population” HKAF
based on their 95th percentile CAss value. This was also the
case of infants, who constituted a mere 1% of the entire
population, for whom less than 90% of the individualsJournal of Toxicology 11
simulated were covered by that same HKAF (Table 6). The
reasons for these results can be determined from Figures
1 and 2. Because toxicokinetically sensitive neonates and
infants make up a small proportion of the population, their
CAss values do not stand out at the right end of the whole
population distributions (Figures 1(a) and 2(a)). Thus, the
“distinct subpopulation-” based HKAF would appear to be
more adequate in these cases because the focus is then put on
the most sensitive subpopulations, regardless of whether the
data follow unimodal or bimodal distributions. Conversely,
when the more sparse individuals (neonates and infants) are
rather less sensitive than the vast majority of the individuals
composing the entire population, as for RAM, the approach
taken to compute the HKAF does not impact its value
(Table 5).
The results obtained in Figures 3 and 4 can be viewed
as a “sensitivity analysis” of the impact of demography on
the HKAF. Replacing a signiﬁcant number of adults from
the Canadian population with individuals who are generally
equallysusceptibleasadults(Table 4)resultedina“younger”
population distribution of CAss for benzene that remained
virtually unchanged (Figure 3(a)). In the case of 1,4-dioxane
(Figure 3(b)), every replacing individual pertained to sub-
populationsthatweremoresusceptiblethanadults(Table 4),
and, as a result, the population distribution of CAss slightly
shifted to the right towards the most susceptible neonates.
In the case of RAM, the individuals replacing the adults
were either more susceptible (pregnant women) or less
susceptible (children), leading to population distributions
that were wider for both chemicals (Figure 4). As mentioned
in Section 3, the sensitivity of the HKAF to the population
demography (i.e., the impact of the population distribution
shift on the estimated HKAF) was marginal because the
diﬀerences in the susceptibilities were not very pronounced
between the subpopulations, with the exceptions of neonates
andinfantsbasedonCAss(particularlyfor1,4-dioxane),and
pregnant women based on the RAM. However, the impact of
these subpopulations’ dose metric on the entire population
distribution always remained minimal because of their small
percentage in the entire population.
While in our study, demography appears to have, at
the most, a very marginal eﬀect on HKAF, the population
distributions of CAss are conversely signiﬁcantly inﬂuenced
by the determining physiological parameters. Indeed, intake
and pulmonary clearance of both benzene and 1,4-dioxane
are driven by alveolar ventilation rate, which is rather log
normally distributed when adjusted to the body weight
(Figure 5(a)). However, blood-ﬂow limited metabolism
results in hepatic blood ﬂow being the determining param-
eter for the clearance of benzene whereas for 1,4-dioxane,
hepatic enzyme concentration and thus Vmax (see (4)) is
determinant of its enzyme-limited clearance. As a result,
the distribution of body-weight-adjusted liver blood ﬂow
(Figure 5(b)), which is more skewed than the distributions
of Vmax (Figure 5(c)) or Clint (central tendency, range:
≈400L/h, 0–1600L/h), yields a population distribution of
CAss that is more skewed for benzene (Figure 1(a)) than for
1,4-dioxane (Figure 2(a)). Indeed, the hepatic clearance of
the latter is rather driven by the Vmax (Figure 5(d)) and the
corresponding Clint (central tendency, range: ≈1.7L/h, 0–
7L/h). Correspondingly, “whole population-” based HKAFs
are smaller for benzene than 1,4-dioxane (Table 5).
The toxicokinetic determinants, including physiological
parameters, of the susceptibility of each subpopulation to
a given chemical based on any dose metric have been
thoroughly discussed elsewhere [16]. Brieﬂy, neonates are
the most susceptible population based on CAss (Table 5)
because they are exposed to a greater-than-adult body-
weight-adjusted dose by inhalation, or to a poorly metabo-
lized chemical (1,4-dioxane) for which hepatic metabolism
is enzyme-limited, thus reduced in neonates. For pregnant
women, their greater susceptibility on the basis of RAM
is due to their increased intake on a body weight basis
(due to high Qp) combined with their eﬃcient hepatic
clearance,a combination that yields a high rate of conversion
of inhaled parent compound into metabolites. Greater
inhalation uptake on a body weight basis and corresponding
blood concentration of inhaled VOCs, for young children
and pregnant women as compared to adults, have been
consistently documented and discussed in the literature [14–
16, 29, 34–39]. The systemic clearance of high Pb,p o o r l y
metabolized 1,4-dioxane is Qp-dependent (for pulmonary
clearance) and enzyme-dependent (for hepatic clearance),
and the greater intrasubpopulation variability of CAss that
was observed for this chemical was expected. This greater
variability results in neonates and infants constituting the
only subpopulation for which the consideration of the 99th
percentile value rather than the 95th signiﬁcantly changes
their HKAF value (Table 5). Else, the intra-subpopulation
variability was rather low for every dose metric.
The “distinct subpopulation-” based HKAFad that was
obtained for benzene exposure in infants (1.3–1.4, Table 5)
and toddlers (1.25–1.33, not shown) was very similar to
the values obtained for other inhaled VOCs by Pelekis
et al. [40] for a 10kg child. Using a deterministic steady-state
approach, these authors obtained an average factor of 1.1 ±
0.6 for eight chemicals highly cleared by either pulmonary
or hepatic clearance or both. Also, a ratio of the neonate’s
95th percentile value to the adult’s median value of blood
concentrations for dichloromethane was slightly above 2 in
the study by Pelekis et al. [41] for continuous inhalation
exposure, as compared to 1.6 for benzene in the current
study. Besides, the “distinct subpopulation-” based HKAFpop
that was obtained in neonates for 1,4-dioxane (6.5, Table 5)
was markedly greater than the value (2) obtained by M¨ ork
and Johanson [17] for acetone, a chemical that is similar to
1,4-dioxane (poorly metabolized and highly water soluble
with a Pb of 260). The HKAF obtained for 1,4-dioxane in
children and adolescents (1.8, not shown) is comparable to
those obtained by these authors for 10 and 15yr old children
for acetone (1.7–2.4). The discrepancy for neonates might
be explained by the diﬀerence in the mean age considered
(14 days versus 3 months) and related hepatic enzyme
content. The “whole population-” based HKAFpop obtained
here based on the 95th percentile (2.1) compares well to
M¨ ork and Johanson’s results (i.e., 1.9). Finally, Renwick and
Lazarus[7]determined thatmorethan99% ofindividuals in12 Journal of Toxicology
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Figure 5: Distributions of individual values obtained for several physiological parameters in each subpopulation within the whole virtual
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a theoretical population of 1 million would be covered by the
default factor, a proportion also obtained in this study.
Among the limitations of this study are other demo-
graphic characteristics, including gender diﬀerentiation, that
could have been considered when generating the population
distributions. In particular, ethnicity can be a critical deter-
minantofpopulationvariabilityintoxicokinetics[7]because
it is often linked to polymorphic metabolism [42]. However,
multiplying subpopulation categories would increase the
uncertainty linked to analyzing the distribution of the dose
metric in very rare individuals like those with genetic
polymorphisms. Besides, gender-related diﬀerences in the
blood toxicokinetics of several VOCs have been considered
insigniﬁcant [38, 43]. Furthermore, ethnicity is likely not
a primary factor determining CYP2E1 activity because the
population variability in the enzyme expression caused by
factors other than polymorphism, such as ethanol consump-
tionandxenobioticcoexposure[44]isconsiderable.Another
limitation relatesto the useof only healthyindividuals in this
study;theHKAFscalculatedthusdonotaccountfordiseased
people with altered hepatic or extrahepatic clearance.
In conclusion, this study has, for the ﬁrst time, system-
atically compared diﬀerent approaches for computing the
HKAF under various assumptions related to the popula-
tion/subpopulation variability in internal dose metric for
continuous inhalation exposure. This was determined for
two environmental chemicals exhibiting diﬀerent patterns of
systemic clearance, to encompass a range of other potential
chemicalswithsuchcharacteristics.Thisstudycontributesto
clarify the implications of the diﬀerent underlying assump-
tions that relate to the interindividual variability considered
when determining the HKAF for any risk management
consideration, including adequate coverage or not of the
most susceptible, but sparse, individuals of a given popula-
tion. In this regard, relying on the “distinct subpopulation”
approach appears more conservative (protective) as it better
covers the most susceptible individuals, in particular if they
compose a small proportion of the general population.Journal of Toxicology 13
Fundamentally, the diﬀerence in the extent of coverage
aﬀorded by these two approaches would appear to depend
upon the proportion of the most sensitive individuals in the
targetpopulationforariskassessment.Moreover,thepresent
work has illustrated the feasibility of a novel approach for
characterizing demography-based population variability of
internal dose metrics for environmental contaminants.
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